Solid Biosciences to Initiate Clinical Program for Gene Therapy Candidate in Coming Months
Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.
Company Expands Presence with London Office to Support Clinical Development.
To advance the development of its gene therapy platform for Duchenne muscular dystrophy.
Please subscribe to receive our latest news